Macrogenics (MGNX) Receivables - Other (2014 - 2015)
Macrogenics (MGNX) posted quarterly Receivables - Other of $900000.0 for Q3 2015, up 118.18% year-over-year from $412500.0 in Q3 2014, and up 12.5% quarter-over-quarter from $800000.0 in Q2 2015.
Macrogenics (MGNX) Receivables - Other (2014 - 2015) Analysis & Trends
Macrogenics (MGNX) has reported Receivables - Other for 2 consecutive years, with $900000.0 the latest figure, recorded in Q3 2015.
- In Q3 2015, Receivables - Other rose 118.18% year-over-year to $900000.0; the TTM figure through Sep 2015 stood at $900000.0 (up 118.18% YoY), while the FY2014 annual figure was $500000.0, changed N/A from the prior year.
- Receivables - Other climbed to $900000.0 in Q3 2015 per MGNX's latest filing, from $800000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $900000.0 in Q3 2015 and bottomed at $0.6 in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 900,000.00 |
| Sep 30, 2015 | 900,000.00 |
| Jun 30, 2015 | 800,000.00 |
| Jun 30, 2015 | 800,000.00 |
| Mar 31, 2015 | 0.60 |
| Mar 31, 2015 | 0.60 |
| Dec 31, 2014 | 500,000.00 |
| Dec 31, 2014 | 500,000.00 |
| Sep 30, 2014 | 412,500.00 |
| Sep 30, 2014 | 412,500.00 |